Αρχική

oncocare logo

Δημοσιεύσεις

ΔΗΜΟΣΙΕΥΣΕΙΣ

Δημοσιεύσεις της Δρ Έλενας Λινάρδου και των ιατρών της Δ’ Ογκολογικής Κλινικής σε διεθνή επιστημονικά περιοδικά με κριτές, όπως καταγράφονται στη βάση PubMed. Τα ονόματα των μελών της ομάδας εμφανίζονται με έντονα γράμματα. Επιλέξτε συγγραφέα για να περιορίσετε τη λίστα ή έτος από το ευρετήριο.

2026 6

  1. Agelaki S, Demiri S, Kotsakis A, …, Linardou H, et al. Epidemiological trends of non-small cell lung cancer and systemic treatment rates as part of initial therapeutic strategy from 2016 to 2020 in Greece: results of the epidemiological part of INFINITY study. BMC Cancer 2026. PubMed
  2. Kosmidis PA, Kosmidis T, Papadopoulou K, …, Linardou H, et al. Comprehensive molecular profiling of advanced NSCLC in Greek patients:A prospective HeCOG study. Cancer Treat Res Commun 2026;48:101310. PubMed
  3. Kosmidis PA, Kosmidis T, Papadopoulou K, …, Linardou H, et al. SNF-CLIMEDIN: A Randomized Trial of Digital Support and Intervention in Patients With Advanced Non-Small Cell Lung Cancer. A Hellenic Cooperative Oncology Group Study. JCO Clin Cancer Inform 2026;10:e2500234. PubMed
  4. Meyer ML, Peters S, Borghaei H, …, Linardou H, et al. Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC. J Thorac Oncol 2026:104111. PubMed
  5. Schiza A, Fountzilas E, Biganzoli L, …, Spathas N, et al. CDK4/6 inhibitor dose patterns among older patients with metastatic breast cancer: A multinational survey study. J Geriatr Oncol 2026;17(7):103068. PubMed
  6. Sebri V, Provenzano L, Monzani D, …, Sarris E, et al. An individualized patient decision-making tool to improve decision making in non-small cell lung cancer: a mixed methods approach. ESMO Real World Data Digit Oncol 2026;13:100730. PubMed

2025 10

  1. Aldea M, Rotow JK, Arcila M, …, Linardou H, et al. Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol 2025;20(11):1594-1614. PubMed
  2. Barlesi F, Yao W, Duruisseaux M, …, Linardou H, et al. Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. Lancet 2025;406(10503):615-626. PubMed
  3. Fountzilas E, Aravantinou-Fatorou E, Dadouli K, …, Spathas N, et al. Real-World Toxicity and Effectiveness Study of Abemaciclib in Greek Patients with Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Multi-Institutional Study. Cancers (Basel) 2025;17(15). PubMed
  4. Fountzilas E, Karageorgopoulou S, Karakatsoulis G, …, Spathas N, et al. Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study. ESMO Real World Data Digit Oncol 2025;7:100095. PubMed
  5. Leighl NB, Paz-Ares L, Abreu DR, …, Linardou H, et al. LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy. J Thorac Oncol 2025;20(10):1489-1504. PubMed
  6. Linardou H, Papadopoulou K, Korfiatis N, …, Spathas N, et al. Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung cancer (PAVE): Final outcome, immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group study. Eur J Cancer 2025;228:115660. PubMed
  7. Mountzios G, Lampaki S, Linardou H, …, Sarris EG, et al. Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the 'EVIDENCE' study. Future Oncol 2025;21(4):447-462. PubMed
  8. Passiglia F, Listì A, Bironzo P, …, Linardou H, et al. Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA). J Thorac Oncol 2025;20(5):614-624. PubMed
  9. Smilkou S, Ntzifa A, Tserpeli V, …, Linardou H, et al. Detection rate for ESR1 mutations is higher in circulating-tumor-cell-derived genomic DNA than in paired plasma cell-free DNA samples as revealed by ddPCR. Mol Oncol 2025;19(7):2109-2119. PubMed
  10. de Langen AJ, Johnson ML, Mazieres J, …, Linardou H, et al. Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary. Future Oncol 2025;21(9):1033-1044. PubMed

2024 5

  1. Ganz-Blaettler U, Liptrott SJ, Tolotti A, …, Linardou H, Sgourou S, et al. The active involvement of patients in oncology research. Cancer Treat Rev 2024;130:102822. PubMed
  2. Sebri V, Marzorati C, Dorangricchia P, …, Sarris E, et al. The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project. Cancer Med 2024;13(9):e7159. PubMed
  3. Smilkou S, Kaklamanis L, Balgouranidou I, …, Linardou H, et al. Direct comparison of an ultrasensitive real-time PCR assay with droplet digital PCR for the detection of PIK3CA hotspot mutations in primary tumors, plasma cell-free DNA and paired CTC-derived gDNAs. Front Oncol 2024;14:1435559. PubMed
  4. Valachis A, Biganzoli L, Christopoulou A, …, Linardou H, Spathas N, et al. Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients. Future Oncol 2024;20(37):2937-2948. PubMed
  5. Waterhouse DM, Rothschild S, Dooms C, …, Linardou H, et al. Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation. Lung Cancer 2024;196:107921. PubMed

2023 11

  1. Galiti D, Linardou H, Agelaki S, …, Sgourou S, et al. Exploring the Use of a Digital Platform for Cancer Patients to Report Their Demographics, Disease and Therapy Characteristics, Age, and Educational Disparities: An Early-Stage Feasibility Study. Curr Oncol 2023;30(8):7608-7619. PubMed
  2. Linardou H, Adjei AA, Bajpai J, et al. Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey. ESMO Open 2023;8(2):100781. PubMed
  3. Linardou H, Lampaki S, Koliou GA, et al. Real-world Data and Economic Evaluation of Nivolumab in Previously Treated Non-small Cell Lung Cancer Greek Patients. Anticancer Res 2023;43(6):2799-2812. PubMed
  4. Mountzios G, Koumarianou A, Linardou H, et al. Clinical Outcomes Beyond 1L EGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study 'LUNGFUL'. Anticancer Res 2023;43(5):2243-2258. PubMed
  5. Mountzios G, Planchard D, Metro G, …, Linardou H, et al. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry. JTO Clin Res Rep 2023;4(1):100433. PubMed
  6. Paz-Ares LG, Ciuleanu TE, Pluzanski A, …, Linardou H, et al. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. J Thorac Oncol 2023;18(1):79-92. PubMed
  7. Prelaj A, Ganzinelli M, Trovo' F, …, Spathas N, Linardou H, et al. The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. Clin Lung Cancer 2023;24(4):381-387. PubMed
  8. Ready NE, Audigier-Valette C, Goldman JW, …, Linardou H, et al. First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. J Immunother Cancer 2023;11(2). PubMed
  9. Reck M, Ciuleanu TE, Lee JS, …, Linardou H, et al. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1. J Thorac Oncol 2023;18(8):1055-1069. PubMed
  10. Sgouros J, Gkoura S, Spathas N, et al. Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug Play a Role?. Clin Colorectal Cancer 2023;22(2):238-244. PubMed
  11. de Langen AJ, Johnson ML, Mazieres J, …, Linardou H, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet 2023;401(10378):733-746. PubMed

2022 10

  1. Apessos A, Agiannitopoulos K, Pepe G, …, Linardou H, et al. Genetic Predisposition to Male Breast Cancer: A Case Series. Anticancer Res 2022;42(12):5795-5801. PubMed
  2. Bota DA, Taylor TH, Lomeli N, …, Linardou H, et al. A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide. Front Oncol 2022;12:934638. PubMed
  3. Fountzilas E, Lampaki S, Koliou GA, …, Linardou H, et al. Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. Cancer Immunol Immunother 2022;71(2):327-337. PubMed
  4. Kokkali S, Kotsantis I, Magou E, …, Spathas N, et al. The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis. Invest New Drugs 2022;40(3):668-675. PubMed
  5. Paz-Ares LG, Ramalingam SS, Ciuleanu TE, …, Linardou H, et al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. J Thorac Oncol 2022;17(2):289-308. PubMed
  6. Sakellakis M, Spathas N, Tsaousis KT, Nikitiadis EN, Linardou H, Diakonis VF Potential Ophthalmological Side Effects Induced by Anti-Neoplastic Regimens for the Treatment of Genitourinary Cancers: A Review. Cureus 2022;14(7):e27266. PubMed
  7. Sioulas A, Spinou M, Schizas D, …, Megapanou M, et al. Pancreatic cystic neoplasms: Adherence to management recommendations and associated endosonographic cyst characteristics. Saudi J Gastroenterol 2022;28(2):122-126. PubMed
  8. Souliotis K, Golna C, Golnas P, …, Linardou H, et al. Lung Cancer Screening in Greece: A Modelling Study to Estimate the Impact on Lung Cancer Life Years. Cancers (Basel) 2022;14(22). PubMed
  9. Spathas N, Goussia AC, Koliou GA, …, Linardou H, et al. Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy-A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study. Cancers (Basel) 2022;14(22). PubMed
  10. Vaz-Luis I, Masiero M, Cavaletti G, …, Linardou H, et al. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Ann Oncol 2022;33(11):1119-1133. PubMed

2021 11

  1. Berghoff AS, Sessa C, Yang JC, …, Linardou H, et al. Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies. ESMO Open 2021;6(6):100281. PubMed
  2. Economopoulou P, Anastasiou M, Papaxoinis G, …, Spathas N, et al. Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC). Cancers (Basel) 2021;13(2). PubMed
  3. Ganzinelli M, Linardou H, Alvisi MF, et al. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. ESMO Open 2021;6(1):100034. PubMed
  4. Garrido P, Adjei AA, Bajpai J, …, Linardou H, et al. Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. ESMO Open 2021;6(3):100131. PubMed
  5. Gouveris P, Zouki DN, Sarris EG, et al. Melanoma and Sarcoidosis in Patients Receiving or Not Antineoplastic Therapy. Case Rep Oncol 2021;14(2):1059-1065. PubMed
  6. Linardou H, Spanakis N, Koliou GA, …, Sgourou S, et al. Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group. Cancers (Basel) 2021;13(18). PubMed
  7. Mountzios G, Koumarianou A, Bokas A, …, Linardou H, et al. A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The 'LUNGFUL' Study. Cancers (Basel) 2021;13(13). PubMed
  8. Mountzios G, Lampaki S, Koliou GA, …, Linardou H, et al. An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece. Lung Cancer (Auckl) 2021;12:93-102. PubMed
  9. Mountzios G, Samantas E, Senghas K, …, Linardou H, et al. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open 2021;6(5):100254. PubMed
  10. Mountzios G, de Toma A, Economopoulou P, …, Linardou H, et al. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. Clin Lung Cancer 2021;22(2):e180-e192. PubMed
  11. Reck M, Ciuleanu TE, Lee JS, …, Linardou H, et al. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1. J Thorac Oncol 2021;16(4):665-676. PubMed

2020 11

  1. Alvisi MF, Ganzinelli M, Linardou H, et al. Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy. J Clin Med 2020;9(8). PubMed
  2. Fountzilas E, Kotoula V, Koliou GA, …, Linardou H, et al. Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget 2020;11(1):1-14. PubMed
  3. Fountzilas E, Koliou GA, Vozikis A, …, Linardou H, et al. Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group. ESMO Open 2020;5(4). PubMed
  4. Friedlaender A, Metro G, Signorelli D, …, Linardou H, et al. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab. Acta Oncol 2020;59(9):1058-1063. PubMed
  5. Laskaratos FM, Armeni E, Shah H, …, Megapanou M, et al. Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms. Endocrine 2020;67(1):233-242. PubMed
  6. Metro G, Banna GL, Signorelli D, …, Linardou H, et al. Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%. J Immunother 2020;43(9):299-306. PubMed
  7. Mountzios G, Mavropoulou X, Koliou GA, …, Linardou H, et al. Impact of Bevacizumab Versus Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group. Anticancer Res 2020;40(4):2095-2106. PubMed
  8. Nicolatou-Galitis O, Papadopoulou E, Vardas E, …, Linardou H, et al. Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. Oral Dis 2020;26(5):955-966. PubMed
  9. Papadopoulou E, Nicolatou-Galitis O, Papassotiriou I, …, Linardou H, et al. The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and/or bevacizumab. Support Care Cancer 2020;28(1):177-184. PubMed
  10. Razis E, Kalogeras KT, Kotsantis I, …, Linardou H, et al. The Role of CXCL13 and CXCL9 in Early Breast Cancer. Clin Breast Cancer 2020;20(1):e36-e53. PubMed
  11. Spathas N, Economopoulou P, Kotsantis I, Oikonomopoulos N, Psyrri A Exceptional Response to Copanlisib in a Heavily Pretreated Patient With PIK3CA-Mutated Metastatic Breast Cancer. JCO Precis Oncol 2020;4:335-340. PubMed

2019 9

  1. Bafaloukos D, Papaxoinis G, Linardou H, et al. Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors. Melanoma Res 2019;29(4):428-434. PubMed
  2. Dimoula M, Kotronoulas G, Katsaragakis S, Christou M, Sgourou S, Patiraki E Undergraduate nursing students' knowledge about palliative care and attitudes towards end-of-life care: A three-cohort, cross-sectional survey. Nurse Educ Today 2019;74:7-14. PubMed
  3. Kotoula V, Tsakiri K, Koliou GA, …, Linardou H, et al. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome. Clin Breast Cancer 2019;19(2):113-125.e4. PubMed
  4. Linardou H, Kotoula V, Kouvatseas G, et al. Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment. Cancer Genomics Proteomics 2019;16(6):531-541. PubMed
  5. Martin-Algarra S, Hinshelwood R, Mesnage S, …, Linardou H, et al. Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program. Melanoma Res 2019;29(5):527-532. PubMed
  6. Metro G, Addeo A, Signorelli D, …, Linardou H, et al. Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort. J Thorac Dis 2019;11(12):4972-4981. PubMed
  7. Mountzios G, Kotoula V, Kolliou GA, …, Linardou H, et al. Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab. ESMO Open 2019;4(2):e000441. PubMed
  8. Ntellas P, Spathas N, Agelaki S, Zintzaras E, Saloustros E Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology. Oncotarget 2019;10(11):1209-1216. PubMed
  9. Spathas N, Belia M, Giannikos T, et al. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma. J BUON 2019;24(6):2483-2489. PubMed

2018 5

  1. Hellmann MD, Ciuleanu TE, Pluzanski A, …, Linardou H, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med 2018;378(22):2093-2104. PubMed
  2. Karavasilis V, Samantas E, Koliou GA, …, Linardou H, et al. Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study. Target Oncol 2018;13(6):715-724. PubMed
  3. Laskaratos FM, Walker M, Wilkins D, …, Megapanou M, et al. Evaluation of Clinical Prognostic Factors and Further Delineation of the Effect of Mesenteric Fibrosis on Survival in Advanced Midgut Neuroendocrine Tumours. Neuroendocrinology 2018;107(3):292-304. PubMed
  4. Spathas N, Economopoulou P, Cheila M, et al. Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma. Front Oncol 2018;8:409. PubMed
  5. Tsavaris O, Economopoulou P, Kotsantis I, …, Spathas N, et al. Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature. Front Oncol 2018;8:45. PubMed

2017 1

  1. Katsi V, Georgiopoulos G, Vogiatzi G, …, Megapanou M, et al. Effects of Oral and Non-Insulin Injectable Antidiabetic Treatment in Hypertension: A Systematic Review. Curr Pharm Des 2017;23(25):3743-3750. PubMed

2016 4

  1. Linardou H, Gogas H Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med 2016;4(14):272. PubMed
  2. Macerelli M, Ganzinelli M, Gouedard C, …, Linardou H, et al. Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?. Cancer Treat Rev 2016;48:8-19. PubMed
  3. Mountzios G, Linardou H, Kosmidis P Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. Ann Transl Med 2016;4(14):268. PubMed
  4. Mountzios G, Aravantinos G, Alexopoulou Z, …, Linardou H, et al. Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia. Mol Clin Oncol 2016;4(2):211-220. PubMed

2015 2

  1. Linardou H, Pentheroudakis G, Varthalitis I, et al. Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin--vinblastine--temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG). Anticancer Res 2015;35(2):1105-13. PubMed
  2. Linardou H, Kalogeras KT, Kronenwett R, et al. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial. Anticancer Res 2015;35(7):4023-36. PubMed

2014 3

  1. Christopoulos A, Saif MW, Sarris EG, Syrigos KN Epidemiology of active tuberculosis in lung cancer patients: a systematic review. Clin Respir J 2014;8(4):375-81. PubMed
  2. Lakis S, Kotoula V, Eleftheraki AG, …, Linardou H, et al. The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. Breast 2014;23(3):234-43. PubMed
  3. Sarris EG, Harrington KJ, Saif MW, Syrigos KN Multimodal treatment strategies for elderly patients with head and neck cancer. Cancer Treat Rev 2014;40(3):465-75. PubMed

2013 4

  1. Fountzilas G, Dafni U, Bobos M, …, Linardou H, et al. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. BMC Cancer 2013;13:163. PubMed
  2. Pentheroudakis G, Kotoula V, Eleftheraki AG, …, Linardou H, et al. Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG). PLoS One 2013;8(7):e70634. PubMed
  3. Sarris EG, Syrigos KN, Saif MW Novel agents and future prospects in the treatment of pancreatic adenocarcinoma. JOP 2013;14(4):395-400. PubMed
  4. Sarris EG, Syrigos KN, Saif MW Pancreatic cancer: updates on translational research and future applications. JOP 2013;14(2):145-8. PubMed

2012 5

  1. Korantzis I, Kalogeras KT, Papaxoinis G, …, Linardou H, et al. Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel. Anticancer Res 2012;32(10):4569-80. PubMed
  2. Linardou H, Kalogeras KT, Kronenwett R, et al. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Breast Cancer Res 2012;14(6):R145. PubMed
  3. Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev 2012;38(7):890-903. PubMed
  4. Psyrri A, Kalogeras KT, Kronenwett R, …, Linardou H, et al. Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. Ann Oncol 2012;23(6):1422-7. PubMed
  5. Sarris EG, Saif MW, Syrigos KN The Biological Role of PI3K Pathway in Lung Cancer. Pharmaceuticals (Basel) 2012;5(11):1236-64. PubMed

2011 3

  1. Dahabreh IJ, Linardou H, Kosmidis P, Bafaloukos D, Murray S EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. Ann Oncol 2011;22(3):545-552. PubMed
  2. Linardou H, Briasoulis E, Dahabreh IJ, et al. All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev 2011;37(3):221-33. PubMed
  3. Pallis A, Briasoulis E, Linardou H, et al. Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations. Curr Med Chem 2011;18(11):1613-28. PubMed

2010 6

  1. Bafaloukos D, Linardou H, Aravantinos G, et al. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. BMC Med 2010;8:3. PubMed
  2. Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2010;16(1):291-303. PubMed
  3. Dahabreh IJ, Linardou H, Bouzika P, Varvarigou V, Murray S TP53 Arg72Pro polymorphism and colorectal cancer risk: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2010;19(7):1840-7. PubMed
  4. Kalofonos HP, Papakostas P, Makatsoris T, …, Linardou H, et al. Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer. Anticancer Res 2010;30(10):4325-33. PubMed
  5. Murray S, Linardou H, Mountzios G, et al. Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature. Mutat Res 2010;686(1-2):68-73. PubMed
  6. Murray S, Bobos M, Angouridakis N, …, Linardou H, et al. Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study. J Oncol 2010;2010:709678. PubMed

2009 2

  1. Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009;6(6):352-66. PubMed
  2. Zagouri F, Linardou H, Dimopoulos AM, Papadimitriou CA Management of advanced stage uterine sarcomas: a bone of contention. Eur J Gynaecol Oncol 2009;30(5):483-92. PubMed

2008 6

  1. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 2008;13(6):620-30. PubMed
  2. Fountzilas G, Bobos M, Kalogera-Fountzila A, …, Linardou H, et al. Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Invest 2008;26(8):784-93. PubMed
  3. Fountzilas G, Dafni U, Gogas H, …, Linardou H, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol 2008;19(5):853-60. PubMed
  4. Koutras AK, Kalogeras KT, Dimopoulos MA, …, Linardou H, et al. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer 2008;99(11):1775-85. PubMed
  5. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9(10):962-72. PubMed
  6. Murray S, Dahabreh IJ, Linardou H, Manoloukos M, Bafaloukos D, Kosmidis P Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol 2008;3(8):832-9. PubMed

2007 1

  1. Karamouzis MV, Linardou H, Papadopoulos G, et al. Gastrointestinal solitary metastases from squamous cell lung cancer. Lung Cancer 2007;55(2):251-2. PubMed

2006 2

  1. Bamias A, Moulopoulos LA, Koutras A, …, Linardou H, et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer 2006;106(2):297-303. PubMed
  2. Murray S, Timotheadou E, Linardou H, et al. Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Lung Cancer 2006;52(2):225-33. PubMed

2005 2

  1. Christodoulou C, Bafaloukos D, Linardou H, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 2005;71(1):61-5. PubMed
  2. Fountzilas G, Pectasides D, Kalogera-Fountzila A, …, Linardou H, et al. Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat 2005;92(1):1-9. PubMed

2004 3

  1. Bafaloukos D, Papadimitriou C, Linardou H, et al. Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group. Br J Cancer 2004;91(9):1639-44. PubMed
  2. Bafaloukos D, Tsoutsos D, Fountzilas G, …, Linardou H, et al. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res 2004;14(4):289-94. PubMed
  3. Linardou H, Aravantinos G, Efstathiou E, et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology 2004;64(3):479-84. PubMed

2003 1

  1. Aravantinos G, Linardou H, Makridaki D, et al. Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: A single-centre randomised study. J BUON 2003;8(2):127-32. PubMed

2001 1

  1. Ong PJ, Linardou H, Graham HA, et al. Tamoxifen is not detrimental to endothelial function in postmenopausal women with breast cancer. Am Heart J 2001;142(4):E6. PubMed

2000 3

  1. Linardou H, Epenetos AA, Deonarain MP A recombinant cytotoxic chimera based on mammalian deoxyribonuclease-I. Int J Cancer 2000;86(4):561-9. PubMed
  2. Samantas E, Kalofonos H, Linardou H, et al. Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study. Ann Oncol 2000;11(11):1395-7. PubMed
  3. Udom DI, Vigushin DM, Linardou H, Graham H, Palmieri C, Coombes RC Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. Eur J Cancer 2000;36(2):177-82. PubMed

1999 1

  1. Palmieri C, Linardou H Breast cancer in women with palpable breast cysts. Lancet 1999;354(9179):677; author reply 678. PubMed

1996 1

  1. Skarlos DV, Aravantinos G, Kosmidis P, …, Linardou H, et al. Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study. Eur J Cancer 1996;32A(3):421-8. PubMed

1994 1

  1. Linardou H, Deonarain MP, Spooner RA, Epenetos AA Deoxyribonuclease I (DNAse I). A novel approach for targeted cancer therapy. Cell Biophys 1994;24-25:243-8. PubMed

1993 2

  1. Epenetos AA, Linardou H New molecular targets and therapeutic strategies against cancer. Int J Biol Markers 1993;8(1):1-7. PubMed
  2. Kosmas C, Linardou H, Epenetos AA Review: advances in monoclonal antibody tumour targeting. J Drug Target 1993;1(2):81-91. PubMed

Δημοσιεύσεις

Κλείστε ραντεβού

Ραντεβού: 210 48 09 150, 210 48 09 160
Καθημερινά 08:00 έως 16:00
oncology.clinic4@gmail.com

Επικοινωνία